Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
e fold » 5 fold (Expand Search), _ fold (Expand Search), 2 fold (Expand Search)
-
221
-
222
-
223
-
224
-
225
A summary of the included study characteristics.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
226
-
227
-
228
-
229
-
230
-
231
-
232
-
233
CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).
Published 2024“…<p>CM-DWM-EC chart using 30% decrease in the mean for the E(KeV).</p>…”
-
234
-
235
WT1 siRNA decreases proliferation, pAKT, and Bcl2 expression.
Published 2024“…</b> RT-qPCR of WT1, p<0.05(*), vFLIP(ns), LANA, p<0.0001(****), K8.1, p<0.0001(****), and BCL2 p<0.05(*) in the setting of WT1 knockdown in ISLK BAC-16 with WT1 siRNA in comparison to a control siRNA using two-sided, unpaired student’s t-tests. …”
-
236
-
237
-
238
-
239
-
240